Verona Foresees FDA End-Of-Phase II COPD Meeting
Talks Will Discuss Pivotal COPD Trials For Ensifentrine
Verona CEO tells Scrip Phase III COPD studies for its lead asset will start next year, take up to two years to complete, leading to commercial launch “probably in 2024.”
You may also be interested in...
The US FDA has slapped a partial clinical hold on Ipsen’s palovarotene clinical trials in rare bone disorders in children less than 14 years old, due to bone growth concerns.
ImCheck’s $53m series B financing will be used to develop antibodies that activate gamma delta T-cells for use against cancer and autoimmune diseases, its CEO tells Scrip.
Novartis’s AI head tells Scrip an open-ended collaboration with Amazon Web Services will ‘transform’ the Swiss major’s global manufacturing operations and distribution centers.